Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors

Autoimmunity

Volumn 45, Issue 3, 2012, Pages 245-252

  Luo, Jie ^a   Lindstrom, Jon ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AChBP; AChR; autoantibodies; MIR; Myasthenia gravis

Indexed keywords

ACETYLCHOLINE BINDING PROTEIN; AUTOANTIBODY; BINDING PROTEIN; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; CONCENTRATION (PARAMETERS); CYTOPLASM; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; MYASTHENOGENICITY; NONHUMAN; RAT; SCORING SYSTEM;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CELL LINE; CROSS REACTIONS; FEMALE; HUMANS; MUSCLES; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEURONS; RATS; RECEPTORS, NICOTINIC;

EID: 84858643464     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.622015     Document Type: Article

References (32)

1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: Past, present, and future. J Clin Invest 2006;116(11):2843-2854. (Pubitemid 44684466)
2. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 2000;23(4):453-477. (Pubitemid 30164770)
3. Vincent A, Palace J, Hilton-JonesD. Myasthenia gravis. Lancet 2001;357(9274):2122-2128.
4. Lindstrom JM, Einarson BL, Lennon VA, Seybold ME. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis. J Exp Med 1976;144(3):726-738.
5. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973;180(88):871-872.
6. Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976;144(3):739-753.
7. Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15(2):185-194. (Pubitemid 17075151)
8. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995;15(2):323-331.
9. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P, Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163:89-120. (Pubitemid 28327864)
10. Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci USA 1982;79(1):188-192. (Pubitemid 12181512)
11. Saedi MS, Anand R, Conroy WG, Lindstrom J. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis. FEBS Lett 1990;267(1):55-59. (Pubitemid 20211699)
12. Conroy WG, Saedi MS, Lindstrom J. TE671 cells express an abundance of a partially mature acetylcholine receptor α subunit which has characteristics of an assembly intermediate. J Biol Chem 1990;265(35):21642- 21651. (Pubitemid 120014207)
13. Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis auto-antibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci 2009;29(44):13898-13908.
14. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001;411(6835):269-276. (Pubitemid 32467026)
15. Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y. Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. Embo J 2005;24(20):3635-3646. (Pubitemid 41509370)
16. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. J Mol Biol 2005;346(4):967-989. (Pubitemid 40215523)
17. Luo J, Kuryatov A, Lindstrom JM. Specific immunotherapy of experimental myasthenia gravis by a novel mechanism. Ann Neurol 2010;67(4):441-451.
18. Lindstrom JM, Lennon VA, Seybold ME, Whittingham S. Experimental autoimmune myasthenia gravis and myasthenia gravis: Biochemical and immunochemical aspects. Ann NY Acad Sci 1976;274:254-274.
19. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia gravis: Cellular and humoral immune responses. Ann NY Acad Sci 1976;274:283-299.
20. Kuryatov A, Luo J, Cooper J, Lindstrom J. Nicotine acts as a pharmacological chaperone to up-regulate human α4β2 acetylcholine receptors. Mol Pharmacol 2005;68(6):1839-1851. (Pubitemid 41654365)
21. Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K, Lindstrom J. Chronic nicotine treatment up-regulates human α3β2 but notα3β4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem 1998;273(44):28721-28732. (Pubitemid 28507559)
22. Vrolix K, Fraussen J, Molenaar PC, Losen M, Somers V, Stinissen P, De Baets MH, Martinez-Martinez P. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010;43(5-6):380-400.
23. SheltonGD, Cardinet GH, Lindstrom JM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology 1988;38(9):1417-1423.
24. Tzartos S, Langeberg L, Hochschwender S, Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett 1983;158(1):116-118. (Pubitemid 13011920)
25. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol 1985;134(4):2343-2349. (Pubitemid 15105635)
26. Hoyer LW, Trabold NC. The significance of erythrocyte antigen site density. II. Hemolysis. J Clin Invest 1971;50(9):1840-1846.
27. Wong JT, Colvin RB. Bi-specific monoclonal antibodies: Selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987;139(4):1369-1374. (Pubitemid 17134197)
28. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. Epitope spreading: Lessons from autoimmune skin diseases. J Invest Dermatol 1998;110(2):103-109. (Pubitemid 28105841)
29. Feferman T, Im SH, Fuchs S, Souroujon MC. Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J Neuroimmunol 2003;140(1-2):153-158. (Pubitemid 36836100)
30. Hohlfeld R, Wekerle H. The role of the thymus in myasthenia gravis. Adv Neuroimmunol 1994;4(4):373-386.
31. Moulian N, Wakkach A, Guyon T, Poea S, Aissaoui A, Levasseur P, Cohen-Kaminsky S, Berrih-Aknin S. Respective role of thymus and muscle in autoimmune myasthenia gravis. Ann NY Acad Sci 1998;841:397-406. (Pubitemid 28362873)
32. Deitiker P, Ashizawa T, Atassi MZ. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of Myasthenia gravis? Hum Immunol 2000;61(3):255-265. (Pubitemid 30117793)